Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 12-year-old male shih tzu dog was diagnosed as having a calcifying epithelial odontogenic tumour. One and a half years prior to presentation, a mass was noticed on the right mandible by the owners. Radiography revealed irregular, faintly radiopaque material within the tumour. A right hemimandibulectomy was performed, based on the clinical diagnosis of osteosarcoma. Histopathological evaluation of the mandibular mass showed that it was composed of a polyhedral odontogenic epithelial cell nest, fibrous stroma, homogeneous eosinophilic material and rounded calcifying material. The eosinophilic material was visualised by staining with Congo red, and observed under green birefringence by polarisation microscopy. Although the tumour had not recurred 12 months after surgery, the dog was euthanased because of aspiratic pharyngitis. The literature on the clinical behaviour of calcifying epithelial odontogenic tumours in dogs and cats is reviewed.
 ...
PMID:Case of calcifying epithelial odontogenic tumour in a dog. 898 Dec 83

The transfer factor (TF) was described in 1955 by S. Lawrence. In 1992 Kirkpatrick characterized the specific TF at molecular level. The TF is constituted by a group of numerous molecules, of low molecular weight, from 1.0 to 6.0 kDa. The 5 kDa fraction corresponds to the TF specific to antigens. There are a number of publications about the clinical indications of the TF for diverse diseases, in particular those where the cellular immune response is compromised or in those where there is a deficient regulation of the immune response. In this article we present our clinical and basic experiences, especially regarding the indications, usage and dosage of the TF. Our group demonstrated that the TF increases the expression of IFN-gamma and RANTES, while decreases the expression of osteopontine. Using animal models we have worked with M. tuberculosis, and with a model of glioma with good therapeutic results. In the clinical setting we have worked with herpes zoster, herpes simplex type I, herpetic keratitis, atopic dermatitis, osteosarcoma, tuberculosis, asthma, post-herpetic neuritis, anergic coccidioidomycosis, leishmaniasis, toxoplasmosis, mucocutaneous candidiasis, pediatric infections produced by diverse pathogen germs, sinusitis, pharyngitis, and otits media. All of these diseases were studied through protocols which main goals were to study the therapeutic effects of the TF, and to establish in a systematic way diverse dosage schema and time for treatment to guide the prescription of the TF.
 ...
PMID:Indications, usage, and dosage of the transfer factor. 1829 53